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Objetives: The extracellular DNA occurring in plasma-EDTA and serum is a biomarker of growing interest, es-
pecially in prenatal diagnosis and oncology. The objectives of the present study were to compare the DNase ac-
tivity in these specimens and to investigate its ex-vivo impact over the circulating cell-free DNA yield (ccfDNA),
using the circulating cell-free fetal DNA (ccffDNA) as a tool.
Design and methods: EDTA-plasma and serum from women bearing male fetus were submitted to an en-
dogenous DNase activity assay based on qPCR hydrolysis probe degradation, they were treated with DNAse I
to investigate the action of an exogenous nuclease and also submitted to different temperature conditions to in-
vestigate the temperature-dependent degradation of the ccffDNA. In all instances, all male ccffDNA were quan-
tiﬁed by qPCR targeting the Y chromosome-speciﬁc sequence DYS-14. Moreover, a serial dilution of EDTA was
added to nonanticoagulated plasma and serum before the endogenous DNAse activity assay, to investigate the
EDTA-mediated inhibition of the blood's DNase.
Results: The endogenous nuclease activity was 14.9-fold higher in serum compared to EDTA-plasma. The
DNAse I treatment did not alter the ccffDNA yields in EDTA-plasma, but completely degraded it in serum. The ad-
dition of increasing doses of EDTA to nonanticoagulated plasma and serum resulted in a stepwise inhibition of
their nucleases activity. Finally, we observed a much more pronounced temperature-mediated decrease on the
ccffDNA amount in serum compared to EDTA-plasma.
Conclusion: The exogenous and endogenous DNases are more active in serum, the anticoagulant EDTA indi-
rectly inhibits blood DNases, and consequently ccfDNA is protected from the blood's DNase preanalytical impact
in EDTA-plasma.
© 2015 The Authors. The Canadian Society of Clinical Chemists. Published by Elsevier Inc. This is an open access
article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Circulating cell-free DNA (ccfDNA) is deﬁned as an extracellular
DNA occurring in the blood [1]. It is a biomarker of growing interest in
various clinical ﬁelds, especially in prenatal diagnosis and oncology.
The analysis of the circulating cell-free fetal DNA (ccffDNA) in the
mother's blood circulation is the method of choice for non-invasive
investigation of the fetus genetic traits. Moreover, the analysis of the
tumor derived from ccfDNA could provide diagnostic and prognostic
information for cancer patients [2].
However, the existence of a DNA degrading activity in the blood is
well established [3] and some authors reported an inverse correlations Clínicas, SHIGN710/711Norte
al, ZIP 70750-531. Fax: +55 61
iety of Clinical Chemists. Publisbetween the circulating DNA yield and blood's DNase activity [4,5].
The DNAse I is the major nuclease present in blood and its products
(e.g., plasma and serum) [3,6,7]. It hydrolyses phosphodiester bonds
of single-strand or double-strand DNA to generate oligonucleotides
and nucleotides with 5′-phospho and 3′-hydroxy termini [8–10].
Despite of these knowledge, blood's DNase impact as a preanalytical
variable for ccfDNA analysis is neither clear norwell studied [11]. To our
knowledge, no study has speciﬁcally links on both subjects. Then we
speculated if the ccfDNA could be susceptible to degradation by DNase
activity present in the biological samples, which would be a factor
affecting ex vivo ccfDNA yields. If DNases are active in the blood
specimens it could be a source of variation (e.g. decrease the sensitivity
of molecular assays).
The ccffDNA inmaternal bloodwould be an invaluable tool to inves-
tigate this issue because placenta cells (trophoblasts) are its primary
source [12], and the supply is lost after the maternal blood draw. In
other words, it means that the ccffDNA quantity cannot increase in thehed by Elsevier Inc. This is an open access article under the CC BY license
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deed, the ccffDNA is present in similar concentrations in maternal
EDTA-plasma and serum [14].
In addition, EDTA-plasma and serum paired samples would be
the second invaluable tool to investigate the questions mentioned
before because the anticoagulant EDTA is an indirect DNase I inhibitor
[7,15,16], since it chelates divalent ions (Ca+2, Mg+2 and Mn+2), which
are essential for the enzyme structure [17] and full enzymatic activity [18].
Thus, the objectives of the present studywere to compare the DNase
activity in EDTA-plasma and serumpaired samples and to investigate its
ex vivo impact over the ccffDNA yield.
2. Materials and methods
2.1. Ethics statement
The health science faculty ethical committee of the University of
Brasilia approved this study (IRB protocol no. 188/12), and written
informed consent was obtained from each participant.
2.2. Subjects, blood collection, processing and transporting
This experimental study enrolled 34 women with male fetus (mean
gestational age, 12 ± 4 weeks). Blood samples were collected simulta-
neously in two 4 mL tubes with gel barrier: Vacuette K2 EDTA Sep and
Vacuette Z serum sep with clot activator (both from Greiner Bio-one).
After the venipuncture, the tubes were both centrifuged for 2,000g for
10min at room temperature (to form a gel barrier), transported to pro-
cessing center at 22± 4 °C and stored at−20 °C until further use. After
thawing, 1000 μL of the supernatants was transferred into polypropyl-
ene tubes, centrifuged at 14,000g for 10 min at room temperature, and
each subsequent experiment was performed with sets of 9–11 paired
supernatants.
2.3. Endogenous DNase activity assay
We used a ﬂuorescence assay to investigate the samples endogenous
DNase activity. Brieﬂy, the assay consisted of 20 μL of the crude EDTA-
plasma or serum, 250 nM of a hydrolysis probe (5′-6-FAM-CTCCAGCTC/
ZEN/CACCTGAACGGCC-IABFQ-3′), 10 μl of 2XMaximaProbe qPCRmaster
mix (Fermentas) and nuclease-free water (Fermentas) to a ﬁnal volume
of 35 μL. The reactions were incubated isothermally at 37 °C for 24 h on
the Step-One qPCR System, and the ﬂuorescencewasmeasured at the be-
ginning of the reaction and every 30 min thereafter. The maxima Probe
qPCR master mix was used as a source of a passive reference dye (ROX),
and the data were shown as deltaRn, which is the FAM ﬂuorescence di-
vided by the ROX ﬂuorescence and them subtracted by the reaction base-
line. The baseline for this assaywas set as the ﬁrst FAMnormalized by the
ROX ﬂuorescence value (Fig. S1). To summarize, this assay investigated
the action of sample's DNase over a single-stranded DNA molecule.
Nuclease-free water and one unit of DNase I (Fermentas) were used as
negative and positive controls, respectively.
2.4. EDTA-mediated inhibition of DNases
A serial dilution of EDTA (Disodium Salt, Dihydrate, USB) was
added to six paired nonanticoagulated plasma and serum samples
before the endogenous DNase activity assay in order to investigate the
EDTA-mediated inhibition of hydrolysis probe degradation. The
nonanticoagulated plasma was prepared through blood draw in plain
tube (Vacuette serum tubes 4 ml, Greiner Bio-one), followed by centri-
fugation at 2,000g for 5 min at room temperature immediately after
venipuncture, the supernatants were transferred into polypropylene
tube and then centrifuged at 14,000g for 10 min at room temperature.
The serum samplewas prepared as described in the blood collection, pro-
cessing and transporting. Thereafter, a 10-fold serial dilution of EDTAfrom 5 × 10−9 to 5 × 10−2 Mwas added to the samples and the endog-
enous nuclease activity assay was performed as described before. The
experimentswere repeated twice, and the dose–response datawere an-
alyzed using the log-dose versus response function of the software
Prism 6.0 (GraphPad).
2.5. Plasma and serum treatments
The specimens were submitted to 37 °C for 24 h and 48 h and to
−20 °C, 4 °C and 22 °C for 24 h in order to investigate the effect of the
temperature over ccffDNA. Furthermore, the samples were treated
with 25 U of DNase I for 1 h at 37 °C in order to assess the action of an
exogenous nucleases on the fetal DNA sequences. All treatments were
performed on EDTA-plasma and serum before the DNA extraction.
2.6. DNA extraction
The DNAwas extracted from 500 μL of each sample by using the ge-
neric protocol 2.0.1 of the NucliSens easyMAG system (bioMerieux),
50 μL of magnetic silica particle suspension and elution in 25 μL.
2.7. Male ccffDNA quantiﬁcation
Male cffDNA were quantiﬁed by amplifying a well-described Y-
chromosome-speciﬁc sequence (DYS-14) [11] in an Step-One qPCR Sys-
tem (Life Technologies) using Maxima Probe qPCR master mix
(Fermentas) and PrimeTime qPCR assay (Integrated DNA Technologies)
consisting of the primers DYS14-F (5′-CCATGACCCCAGAGTCTGC-3′)
and DYS14-R (5′-CTTCCTGGCTTGGGCATTAAC-3′) and hydrolysis
probe (5′-6-FAM-CTCCAGCTC/ZEN/CACCTGAACGGCC-IABFQ-3′) as rec-
ommended by the manufactures. The cycle conditions were as follows:
pre-incubation for 10min at 95 °C, followed by 60 cycles of 15 s at 95 °C
and 60s at 60 °C. The reaction volume was 24 μL, including 10 μL of the
eluate. The equation describing the DYS-14 calibration curve was
Y=−3.26X+ 29.75 (efﬁciency = 102.45% and R2 = 0.998). All sam-
ples were run in duplicate and each run included two negative controls.
The quantity ofmale DNA in genomic equivalents (GE) per PCR reaction
was determined by comparison with a 5-fold dilution series of the 007
control (life technologies), 151, 30.2, 6.02, 1.21 and 0.24GE. The conver-
sion factor of 6.6 pg of DNA per genome was used and the DYS-14
concentration in GE/mL was calculated as described before [14]. The
qPCR experiments and description followed the minimum information
for qPCR experiments guideline (MIQE) [19].
2.8. Statistical analysis
The statistical method used was Wilcoxon's matched-pairs signed
rank test. All graphs and statistical analysis were performed using the
software Prism 6.0.
3. Results
3.1. Endogenous and exogenous DNase activities in EDTA-plasma and
in serum
In the endogenousDNase activity assay,we observed a sustained hy-
drolysis probe degradation in serum over time, whichwas not observed
in EDTA-plasma. In EDTA-plasma, the probe degradation reached a pla-
teau at 1–3 h of reaction (Fig. 1). Considering the reaction's last reading
point, the median deltaRn was 14.9-fold higher in serum compared to
the paired EDTA-plasma (median 1.64 deltaRn versus 0.11 deltaRn,
p= 0.0156) (Fig. S2).
The treatment with DNase I showed no change of the median
ccffDNA amount in EDTA-plasma (untreated 17.86 GE/mL versus treat-
ed 19.68 GE/mL, p = 0.35) (Fig. 2A) but degraded it to undetectable
Fig. 1. Representative endogenous DNase activity assay in EDTA-plasma and serum paired samples of 5 subjects. In 24 h, the hydrolysis probe degradation was higher in serum (open
circles) compared to the matched EDTA-plasma (closed circles), suggesting that the blood DNA degrading activity was inhibited in EDTA-plasma. The negative control (closed square)
showed negligible levels of hydrolysis probe degradation. The positive control (open square) showed hydrolysis probe degradation kinetic that was not as continuous as the serum
samples. We cannot distinguish if this effect was secondary to a higher DNases amount in the serum together with presence of inhibitors or if it was a complex composition of DNA
degrading enzymes.
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Fig. 2. Before-and-after plot showing the effect of DNAse I treatment on ccffDNA yields in EDTA-plasma and serum. (A and B) The specimens were treated (+) or not (−) with 25U of
DNAse I for one hour at 37 °C before the cffDNA measurement. Each line represents one-studied sample (n= 10). The ccffDNA was completely degraded in the serum sample, but not
in plasma-EDTA meaning that this exogenous nuclease was inhibited in the latter specimen.
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(Fig. 2B).
3.2. EDTA dose-dependent inhibition of nucleases in fresh plasma and in
serum
The additions of a 10-fold serial dilution of EDTA to nonanticoagulated
plasma and to serum (Fig. S3) before the endogenous nuclease activity
assay showed a stepwise inhibition of the hydrolysis probe degradation
in both specimens. The IC50 ranged from 1.46 × 10−4 M to
5.70 × 10−5 M in nonanticoagulated plasma and from 1.09 × 10−4 M to
6.66 × 10−5 M in serum.
3.3. Temperature effect over ccffDNA in EDTA-plasma and serum samples
The initial ccffDNA concentration was 1.4-fold higher in EDTA-
plasma than in the matched serum (27.40 versus 18.57 GE/mL)
(Fig. 3A versus 3B at 0 h). In the ﬁrst 24 h, the exposure at 37 °C resulted
in a decrease on the ccffDNA concentration of 1.07-fold in EDTA-plasma
(median 27.40 GE/mL versus 25.55 GE/mL, p = 0.07) and 3.52-fold in
serum (median 18.57 GE/mL versus 5.26 GE/mL, p = 0.001). In the
next 24 h, the reduction in the ccffDNA yields was 1.02-fold (median
25.55 GE/mL versus 24.83 GE/mL, p = 0.24) and 1.68-fold (median
5.26 GE/mL versus 3.13 GE/mL, p = 0.001) for EDTA-plasma and
serum, respectively. Considering the total experiment time (48 h), the
ccffDNA degradation was 1.10-fold (median 27.40 GE/mL versus 24.83
GE/mL, p= 0.001) in EDTA-plasma and 5.9-fold (median 18.57 GE/mL
versus 3.13 GE/mL, p= 0.001) in serum (Fig. 3A and B).
Next, samples were subjected to the pragmatic transportation and
storage temperatures for 24 h. The median ccffDNA concentration in
EDTA-plasma was similar during the experiment duration, 40.27 GE/mL
for−20 °C, 42.25 GE/mL for 4 °C and 41.45 GE/mL for 22 °C (Fig. 3C).
In serum, the same observation was made for−20 °C and 4 °C (20.72
versus 19.89 GE/mL, p= 0.91), on the other hand, a 1.6-fold and 1.54-
fold decreases were observed at 22 °C (12.88 GE/mL) compared to
−20 °C and 4 °C, respectively (p= 0.0039 for both) (Fig. 3D).
4. Discussion
In this study, we compared the DNase activity in EDTA-plasma and
serum samples and investigated its ex vivo impact over the ccffDNA
yield. Our ﬁrst ﬁnding, that endogenous and exogenous DNases were
more active in serum, is supported by the observation of sustained
hydrolysis probe degradation over the reaction time in this specimen.
Conversely, we observed a deltaRn increase in EDTA-plasma, but it
reached a plateau in the beginning of the reaction and no furtherﬂuorescence change was observed in the remaining 21–23 h. In addi-
tion, the treatmentwith a high amount of DNase I degraded the ccffDNA
in serum, but not on ccffDNA in EDTA-plasma. Taken together, these re-
sults suggested that sample's DNase activity is a preanalytical variable
which could affect the ccffDNA yields in serum more extensively than
in plasma-EDTA.
Furthermore, in the endogenous DNase assay the probe degradation
kinetics of the reaction positive control (1 U of DNase I) was different
from the serum samples. This observation should be secondary to the
fact that total DNase activity in the serum sample is dependent on the
complex combination of the concentration and composition of the DNA
degrading enzymes and unknown factors inﬂuencing their activity [6].
Our second ﬁnding was the evidence that EDTA indirectly inhibits
the sample's DNase activity, probably by chelation of divalent ions.
Adding increasing doses of EDTA to nonanticoagulated plasma and
serum samples resulted in a stepwise inhibition of the enzymatic activ-
ity. The K2EDTA concentration in the gel barrier tubes used in this study
was 1.8 mg per mL of blood (4.5 × 10−3 M), and the anticoagulant
amount contained in the regular EDTA-plasma tubes ranges from 1.5
to 2.0 mg per mL of blood [20]. We observed a very important, but not
complete, inhibition of the DNase activity in the dose–response curves
at this concentration (5 × 10−3 M). Similar conclusion can be draw
from the small but still detectable nuclease activity found in EDTA-
plasma samples. Taken together, these results suggested that themolec-
ular tests based on the ccfDNA analysis would beneﬁt from a 10-fold
increase of EDTA concentration in the collection tube since no or
negligible DNAse activity was observed at 5 × 10−2 M.
Furthermore, the EDTA IC50 for nonanticoagulated plasma and
serum were similar, suggesting that equal concentration of this antico-
agulant is able to elicit the same inhibitory effects in both specimens
[21]. We observed similar DNA degrading activity in nonanticoagulated
plasma compared to the paired serum, although theywere different be-
tween the individuals.
Our third ﬁnding, that ccffDNA is protected from a temperature-
triggered degradation in EDTA-plasma, was supported by our exposi-
tion experiments. At 37 °C, the ccffDNA concentration showed a greater
decrease in serum compared to EDTA-plasma probably because EDTA
indirectly inhibited DNase activity in the latter specimen. These obser-
vations conﬁrmed that blood DNase activity could exerts its effects
on the sample ex vivo and it can lower the ccffDNA yields in the bio-
logical samples. However, despite the EDTA inhibition, the small but
still detectable nuclease activity found in EDTA-plasma samples lead
to an almost signiﬁcant reduction of the ccffDNA yield in the ﬁrst
24 h and signiﬁcant reduction after 48 h. The elimination of this re-
sidual enzyme activity in the EDTA-plasma should increase ccfDNA
stability.
Fig. 3.Before-and-after plot showing the effect of temperature over ccffDNA in EDTA-plasma and serum. (A and B) Basal (0 h) and after exposure to 37 °C for 24 h and 48 h (n=11).
(C and D) Samples exposed to−20 °C, 4 °C and 22 °C for 24 h. Each line represents one-studied sample (n = 9). The results showed that ccffDNA was protected from sample's
DNAse activity in plasma-EDTA and the DNA degrading activity in serum was a temperature-triggered mechanism.
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clinical laboratories, no differences were observed in ccffDNA at
−20 °C and 4 °C in both specimens, otherwise, a decrease occurs at
22 °C in serum but not in plasma-EDTA. These evidences suggested
that sample's DNase activity is a temperature-triggered mechanism
and a preanalytical factor that is more important to serum samples.
Therefore, the consistently lower initial ccffDNA yield in serum com-
pared to the EDTA-plasma found in our paired samples could be second-
ary to the transportation at 22 ± 4 °C to processing center, we cannot
exclude the potentially contribution of the higher maternal DNA back-
ground in serum for this observation. Thus, in the ccfDNA ﬁeld strictly
low-temperature condition control should be applied to serumsamples.
On the other hand, it can be more ﬂexible for plasma-EDTA.
Actually, several preanalytical considerations for ccfDNA and
ccffDNA analysis have been studied, and EDTA-plasma is the matrix of
choice because it ensured the stability of the analyte and also because
of its low contamination with leukocyte's genomic DNA [2]. Many stud-
ies have already demonstrated that the ccffDNA remained stable for24 h after phlebotomy in EDTA-plasma and concluded that it can be
measured in referral laboratories after the sample has been shipped
overnight [11,22]. Others have described better results using plasma-
EDTA compared to serum [23,24]. All these evidences supported our
conclusion that EDTA inhibits the sample's DNase activity and protects
ccffDNA ex vivo in biological samples. Indeed, the EDTA provides the
higher ccffDNA stability observed in EDTA-plasma.
Finally, the protection conferred by EDTA can be extrapolated for
other DNA targets, and the use of this anticoagulant should mitigate
preanalytical effects of blood nucleases. Furthermore, our group con-
ceived independently the endogenous DNase activity assay used in
this study; however, previous similar protocols were identiﬁed after lit-
erature research [25,26]. In conclusion, these evidences showed that the
blood DNases are active in serum and the widely used anticoagulant
EDTA also works as an indirect blood's DNase inhibitor that avoids ex
vivo degradation of the ccfDNA.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.clinbiochem.2015.02.014.
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